Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Cancer|August 15, 1983
Doxorubicin and CCNU with or without vincristine in patients with advanced refractory breast cancer. A randomized trialR T Chlebowski, R Pugh, J M Weiner, et al.
Cancer Treatment Reports|March 1, 1984
Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic resultsR T Chlebowski, A Brzechwa-Adjukiewicz, A Cowden, et al.
Clinical Nuclear Medicine|May 1, 1987
Exercise-induced muscle uptake of technetium-99m MDPR P du Cret, R J Boudreau, J B Block, et al.
Cancer Treatment Reports|December 1, 1977
Pharmacokinetics of high-dose methotrexate with citrovorum factor rescueW H Isacoff, P F Morrison, J Aroesty, et al.
Medical and Pediatric Oncology|January 1, 1976
High dose methotrexate therapy of solid tumors: observations relating to clinical toxicityW H Isacoff, C M Townsend, F R Eiber, et al.
The American Journal of Clinical Nutrition|April 1, 1990
Fecapentaene excretion: aspects of excretion in newborn infants, children, and adult normal subjects and in adults maintained on total parenteral nutritionJ B Block, M F Dietrich, R Leake, et al.
American Journal of Clinical Oncology|April 1, 1985
Doxorubicin, cyclophosphamide, CCNU, and vincristine with or without cisplatinum in non-small cell lung cancerR T Chlebowski, J S Chlebowski, J Herrold, et al.
American Journal of Surgery|July 1, 1976
Local delayed cutaneous hypersensitivity reactions in breast cancer patients with and without removal of axillary lymph nodesP M Schick, M M Shabot, J B Block, et al.
American Journal of Surgery|October 11, 1975
High dose methotrexate as a preoperative adjuvant in the treatment of epidermoid carcinoma of the head and neck. A feasibility study and clinical trialJ L Tarpley, P B Chretien, J C Alexander, et al.
Cancer Research|December 1, 1989
Antimutagenic effects of taurine in a bacterial assay systemS A Laidlaw, M F Dietrich, M P Lamtenzan, et al.
Pageof 3